PBI
60
2
CMCSA
46
-2
SYY
58
2
PSA
66
-2
FIS
51
-2
MMM
50
-2
AAL
50
8
CL
59
-2
MOS
20
4
RSG
57
-7
NAVI
57
2
CSCO
48
-5
MU
28
2
CSX
60
2
PPL
67
-2
CHD
56
-2
TMO
58
-2
AVGO
40
-24
EQIX
60
-3
TROW
34
2
PBI
60
2
CMCSA
46
-2
SYY
58
2
PSA
66
-2
FIS
51
-2
MMM
50
-2
AAL
50
8
CL
59
-2
MOS
20
4
RSG
57
-7
NAVI
57
2
CSCO
48
-5
MU
28
2
CSX
60
2
PPL
67
-2
CHD
56
-2
TMO
58
-2
AVGO
40
-24
EQIX
60
-3
TROW
34
2
Financhill
Back

NovaBay Pharmaceuticals 10K Form

Sell
29

NBY
NovaBay Pharmaceuticals

Last Price:
0.51
Seasonality Move:
-14.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NBY News And Ratings

See the #1 stock for the next 7 days that we like better than NBY

NBY Financial Statistics

Sales & Book Value

Annual Sales: $14.73M
Cash Flow: $-580K
Price / Cash Flow: 0
Annual Sales: $-0.46
Price / Book: 0

Profitability

EPS (TTM): -48.14620
Net Income (TTM): $-10.66M
Gross Margin: $7.9M
Return on Equity: -288.89%
Return on Assets: -113.02%

NovaBay Pharmaceuticals Earnings Forecast

Key NovaBay Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 21 years for NBY is 53.61%.
  • The Selling, General & Administrative Expenses for NBY have been equal to 87.12% of Gross Profit Margin.
  • The Research & Development expenses have been 0.46% of Revenue.
  • The Net Earning history of NBY is -65.46% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 11 years.

NovaBay Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: NBY
CUSIP: 66987P
Website: novabay.com

Debt

Debt-to-Equity Ratio: -1.13
Current Ratio: 0.62
Quick Ratio: 0.36

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NBY Technical Analysis vs Fundamental Analysis

Sell
29
NovaBay Pharmaceuticals (NBY) is a Sell

Is NovaBay Pharmaceuticals a Buy or a Sell?